Bioheart restructures top management

South Florida's Bioheart has shaken up its management team. In addition to assuming the position of chairman of the board, Karl E. Groth, Ph.D., became the CEO; Peggy A. Farley became chief operating officer; and Mark P. Borman became CFO. Former CEO Howard Leonhardt will continue as chief scientific and technology officer and chairman of the Scientific Advisory Board.

Discovery Labs announced the resignation of Robert Capetola, its CEO since the company's founding 13 years ago. Board Chairman Thomas Amick, a Johnson & Johnson alum, has been appointed as interim CEO.

GENova Biotherapeutics named Aaron Whiteman as its chief executive officer.

Winston Pharmaceuticals announced that Joel E. Bernstein, M.D., the founder of Winston Laboratories, a wholly-owned subsidiary, will remain as president and CEO for the duration of the term set forth in his employment agreement with the company.

Kolltan Pharmaceuticals has named Stanley Choy to the newly created position of vice president finance and treasurer and W. Bradford Middlekauff to the newly created position of chief legal officer, general counsel and secretary. The company also elected four external members to its board: Axel Bolte; K. Peter Hirth, Ph.D; Thomas B. Neff and E. Jonathan Soderstrom, Ph.D.

PharmAthene announced that Charles A. Reinhart III has been appointed to the position of senior vice president, chief financial officer. Christopher C. Camut has been appointed to the newly created position of vice president, government contracting and special projects.

Symphogen announced that Adriann Sax has joined the company's management team as chief business officer.

Robert Kohn has joined Proteonomix as acting CFO.

John Sweeney has been named to lead the life sciences division at Millipore.

Oncodesign Biotechnology has named Jan Hoflack as vice president, drug discovery.

ImmunoGen named Peter Williams as vice president, business development.

Lycera has named five scientists and clinicians to its Scientific Advisory Board. They are: Jonathan A. Ellman, Ph.D., professor of chemistry at the University of California, Berkeley; David J. Mangelsdorf, Ph.D., chair of the Department of Pharmacology at University of Texas Southwestern Medical Center at Dallas; Ruslan Medzhitov, Ph.D., professor of immunobiology at Yale University School of Medicine; Michael E. Weinblatt, M.D., co-director of clinical rheumatology at the Brigham and Women's Hospital and professor of medicine at Harvard Medical School; and Arthur Weiss, M.D., Ph.D., chief of the Division of Rheumatology in the Department of Medicine at the University of California, San Francisco. 

Cannabis Science says that Dr. Ritchard L. Fishman has accepted its request to become a member of its recently formed Scientific Advisory Board.

Helix BioPharma announced the appointment of Kazimierz Roszkowski-Sliz, M.D., Ph.D., to its board of directors.

BioTime has appointed Pedro Lichtinger to its board of directors.

Ambrilia Biopharma announced that Dr. Philippe Calais, the former president and CEO, has resigned from the board.

XenoPort has named Dennis M. Fenton, Ph.D., to its board of directors.

Thallion Pharmaceuticals announced the resignation of Francois Legault from its board.

Alios BioPharma has appointed Plexxikon founder and CEO K. Peter Hirth, Ph.D., to its board of directors.

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.